Every Form 4 that Exagen Inc. (XGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XGN filings page.
EXAGEN INC. (XGN) reported that its Chief Financial Officer, Jeffrey G. Black, had mixed equity activity on September 1, 2026. He sold 20,614 shares of common stock at an average price of $7.2175 per share to cover tax withholding on vesting Restricted Stock Units, a transaction mandated by the company. On the same date, he acquired 1,571 shares of common stock at $3.0175 per share through the company’s Employee Stock Purchase Plan.
EXAGEN INC. (XGN) director Bruce C. Robertson reported a grant of 37,500 stock options on June 9, 2026. The options have an exercise price of $4.31 per share, are exercisable for 37,500 shares of common stock, and expire on June 8, 2036. The award becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued board service. An earlier Form 4 had overstated his post-grant holdings; this amendment clarifies that he beneficially owns 37,500 stock options in total.
EXAGEN INC. (XGN) director Bruce C. Robertson reported an award of a stock option covering 37,500 shares of common stock at an exercise price of $4.31 per share on June 9, 2026. The option expires on June 8, 2036 and becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual stockholders’ meeting, contingent on his continued board service. Following this grant, he holds options on 55,500 shares directly.
EXAGEN INC. (XGN) reported that director Paul Kim received a grant of stock options. On 2026-06-09, he was awarded 37,500 stock options to purchase common stock at an exercise price of $4.31 per share, expiring on 2036-06-08. These options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued board service. Following this grant, Kim holds 46,500 options directly.
EXAGEN INC. director Scott D. Kahn reported receiving a stock option grant covering 37,500 shares of common stock. The option has an exercise price of $4.31 per share and expires on June 8, 2036.
According to the terms, all 37,500 option shares become fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Kahn continues to serve on the board through that date. After this grant, he directly holds options on 46,500 shares.
Exagen Inc. director Chas McKhann received a grant of stock options covering 37,500 shares of common stock at an exercise price of $4.31 per share. These options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service. Following this grant, McKhann holds options on 45,000 shares in total, which are scheduled to expire on June 8, 2036.
EXAGEN INC. director Frank Stokes received a grant of stock options for 37,500 shares of common stock at an exercise price of $4.31 per share. These options vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service.
Exagen Inc. Chief Financial Officer Jeffrey G. Black reported several equity-based compensation awards and a plan purchase. He received a stock option for 50,000 shares of common stock at $3.16 per share, expiring in 2036 and vesting over time, with potential full vesting upon certain change-in-control terminations.
He was also granted 75,000 restricted stock units, each representing one share of common stock, which vest in four equal annual installments starting on February 21, 2026, subject to continued service and similar change-in-control provisions. In addition, he acquired 1,511 shares of common stock at $3.077 per share through Exagen’s Employee Stock Purchase Plan. Following these grants and the ESPP purchase, he directly held 343,953 shares of common stock.
ABALLI JOHN reported acquisition or exercise transactions in this Form 4 filing.
EXAGEN INC. President and CEO John Aballi reported new equity compensation awards. He received stock options for 100,000 shares at $3.1600 per share, expiring on March 11, 2036, and a grant of 150,000 shares of common stock at no cost.
The 150,000-share award consists of restricted stock units that vest 25% on each of the first four anniversaries of February 21, 2026, with potential full vesting upon certain change-in-control terminations. The options vest 25% on February 21, 2027, then 1/48 of the total each month, with similar change-in-control protection.
After these awards, Aballi directly holds 839,834 shares of common stock and 175,000 stock options, and there are an additional 40,401 shares held indirectly by his spouse.
Exagen Inc. President and CEO John Aballi reported both a sale and a purchase of company stock. He sold 15,698 shares of common stock at an average price of $3.62 per share, with the sale carried out at the issuer’s direction solely to cover tax withholding on vested restricted stock units, not as a discretionary trade. He also acquired 2,535 shares of common stock at $3.077 per share through the company’s Employee Stock Purchase Plan, a plan-based share purchase. After these transactions, he directly held 689,834 common shares, and an additional 40,401 shares were held indirectly by his spouse.
EXAGEN INC. reported an insider transaction by President and CEO John Aballi involving a mandatory share sale to cover taxes. On this Form 4, Aballi sold 11,430 shares of common stock at $3.61 per share, with the sale directed by the company solely to satisfy tax withholding obligations tied to vesting and settlement of restricted stock units. The filing states this was not a discretionary trade by Aballi. Following the transaction, he directly held 702,997 common shares, and there is an additional indirect holding of 40,401 shares reported as owned by his spouse.
EXAGEN INC. Chief Financial Officer Jeffrey G. Black reported an open-market sale of 1,584 shares of common stock at a price of $3.61 per share. After this transaction, he directly owned 267,442 shares of the company’s stock.
According to the footnote, the sale was carried out at the direction of the company solely to cover tax withholding obligations arising from the vesting and settlement of Restricted Stock Units. It is described as a mandated transaction rather than a discretionary sale by the executive.
Exagen Inc. (XGN) disclosed an insider transaction by its President and CEO, who is also a Director. On 10/16/2025, he sold 31,787 shares of common stock at $11.8161 per share, coded “S.”
According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding on the vesting and settlement of Restricted Stock Units, and it was not a discretionary transaction by the reporting person.
Following the transaction, the reporting person beneficially owned 714,427 shares directly, plus 40,401 shares indirectly held by spouse.